AJCN Tufts Nutrition Symposium, Boston Sept 24-26
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LEVEILLE, G. A.
Right arrow Articles by NUNES, W. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEVEILLE, G. A.
Right arrow Articles by NUNES, W. T.
Agricola
Right arrow Articles by LEVEILLE, G. A.
Right arrow Articles by NUNES, W. T.

American Journal of Clinical Nutrition, Vol 12, 421-426, Copyright © 1963 by The American Society for Clinical Nutrition, Inc.

Effect of Orally and Parenterally Administered Neomycin on Plasma Lipids of Human Subjects

GILBERT A. LEVEILLE PH.D.1, RICHARD C. POWELL M.D.1, HOWERDE E. SAUBERLICH PH.D.1, and WILLIAM T. NUNES MC, U.S.A.1

1 From the U. S. Army Medical Research and Nutrition Laboratory, Fitzsimons General Hospital, Denver, Colorado

Neomycin, when administered intramuscularly to human subjects at the rate of 200 mg. per day, did not influence plasma cholesterol levels. This same dose administered orally also was without influence, although in four of the six subjects fecal coliform counts were suppressed. When the amount of neomycin administered orally was increased to 2.0 gm. per day, the same four subjects had stools which were negative for coliform organisms; however, all six subjects demonstrated a highly significant decrease in plasma cholesterol levels. The 2.0 gm. per day level of neomycin also significantly depressed lipid digestibility.

The data are interpreted to indicate that neomycin therapy lowers plasma cholesterol levels by interfering with normal intestinal absorption of lipids and sterols and possibly the recirculation of bile acids and that the hypocholesteremic effect of neomycin is not the result of a systemic effect.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1963 by The American Society for Nutrition